<DOC>
	<DOCNO>NCT00334529</DOCNO>
	<brief_summary>This study determine oseltamivir ( Tamiflu ( Registered Trademark ) ) safe effective give less frequently currently prescribe dose twice day 5 day people flu , day 6 week people expose someone else flu want prevent get . This study see drug give every day instead daily give another medication call probenecid ( Benemid ( Registered Trademark ) Probalan ( Registered Trademark ) ) . Healthy people 18 year age old may eligible study . Candidates screen medical history , physical examination , blood urine test . Participants randomly assign one follow regimens 2 week : 1 ) 75 milligram ( mg ) oseltamivir day ; 2 ) 75 mg oseltamivir every day plus 500 mg probenecid four time day ; 3 ) 75 mg oseltamivir every day plus 500 mg probenecid twice day . All medication take mouth . On study day 0 , subject follow baseline procedure : measurement vital sign , review medical medication history , physical examination , blood draw urine test . They also receive first dose oseltamivir oseltamivir probenecid . In addition , undergo follow procedure follow : - Days 1 4 : Vital sign ; review clinical symptom , side effect medication take ; urine test blood draw . - Day 8 : Same day 1 plus count study medication . - Day 14 : Same day 8 plus pharmacokinetic study measure amount oseltamivir probenecid blood . For test , catheter insert arm vein blood sample collect catheter take study medication , time medication take , 15 minute , 30 minute , 45 minute 1 , 1.5 , 2 , 4 , 8 12 hour medication take . The catheter remove . This last day take study medication . - Day 15 : Blood draw 24-hour ( post medication ) blood sample . - Day 16 : Blood draw 48-hour ( post medication ) blood sample . - Days 21 28 : Same day 1 .</brief_summary>
	<brief_title>Alternative Oseltamivir Dosing Strategies</brief_title>
	<detailed_description>Pandemic influenza infection potential causing significant morbidity mortality United States elsewhere . Oseltamivir ( Tamiflu [ R ] ) selective inhibitor influenza virus neuraminidase U.S. FDA approve treatment prophylaxis influenza A B virus . However , time national emergency , supply oseltamivir may limit alternative dose strategy may need order provide wide protection possible influenza treat many infected patient possible . Agents Probenecid may extend half-life oseltamivir maintain effective oseltamivir plasma level may potentially useful regard . In multi-center , three-arm , open-label , 48 patient trial , propose explore relative safety pharmacokinetics oseltamivir plus Probenecid 14 day normal volunteer age 65 , accord follow dosing strategy : 16 subject assign Group I Control Arm ( Tamiflu [ R ] 75 mg give orally daily ) , 16 subject assign Group II Treatment Arm ( Tamiflu [ R ] 75 mg orally every day plus Probenecid 500 mg orally four time daily ) , 16 subject assign Group III Treatment Arm ( Tamiflu [ R ] 75 mg orally every day Probenecid 500 mg orally twice daily ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects include male nonpregnant female 18 year old . Subjects understand study potential safety concern sign inform consent form prior admission study . Subjects willing complete require assessment , test evaluations able make study visit . 1 . Hemoglobin great equal 10.0 g/dL male great 9.0 g/dL female ; 2 . Platelet count great equal 75,000 /micro L ; 3 . Absolute neutrophil count great equal 1000 /micro L ; 4 . SGOT SGPT less 2.5 time normal upper limit ; 5 . Serum uric acid WNL ; 6 . Creatinine le 1.5 time normal upper limit ( normal UL 1.5 mg/dL ) less 65 year age group must within normal limit great equal 65 year age group ; 7. creatinine clearance great equal 50 mL/min . EXCLUSION CRITERIA : Subjects creatinine clearance less 50 mL/min ( measure CockcroftGault method ) Subjects pregnant breast feeding female Subjects employ adequate contraception Subjects drug alcohol abuser opinion investigator would interfere subject compliance safety Subjects currently participate clinical research study Any acute serious infection require prescription therapy within 14 day prior Day 0 study Subjects G6PD deficiency Subjects may recently expose influenza Subjects gout , blood dyscrasia , history hypersensitivity sulfonamide drug Subjects contraindication study medication History allergic reaction probenecid Have kidney disease , kidney stone , poorly function kidney Have active peptic ulcer disease On high dose aspirin dose nonaspirin salicylate therapy Receiving follow medication ( relative contraindication probenecid ) : Acyclovir , allopurinol , penicillamine , clofibrate , rifampin , methotrexate , zidovudine , theophylline , dapsone , penicillins cephalosporin , nonsteroidal antiinflammatory drug ( NSAIDS ) ibuprofen ( Motrin , Advil , Nuprin , others ) , ketoprofen ( Orudis , Oruvail , Orudis KT ) , diclofenac ( Cataflam , Voltaren ) , etodolac ( Lodine ) , fenoprofen ( Nalfon ) , flurbiprofen ( Ansaid ) , indomethacin ( Indocin ) , ketorolac ( Toradol ) , nabumetone ( Relafen ) , oxaprozin ( Daypro ) , piroxicam ( Feldene ) , sulindac ( Clinoril ) , tolmetin ( Tolectin ) , naproxen ( Aleve , Anaprox , Naprosyn ) ; sulfabased medication sulfamethoxazole ( Bactrim , Septra , Gantanol ) , sulfasalazine ( Azulfidine ) , sulfinpyrazone ( Anturane ) , sulfisoxazole ( Gantrisin ) , others ; oral diabetes medicine glipizide ( Glucotrol ) , glyburide ( Micronase , Diabeta , Glynase ) , tolbutamide ( Orinase ) , tolazamide ( Tolinase ) ; barbiturate phenobarbital ( Luminal , Solfoton ) , amobarbital ( Amytal ) , secobarbital ( Seconal ) , others ; benzodiazepine ( use treat anxiety panic disorder induce sleep ) alprazolam ( Xanax ) , diazepam ( Valium ) , lorazepam ( Ativan ) , temazepam ( Restoril ) , chlordiazepoxide ( Librium ) , clonazepam ( Klonopin ) , clorazepate ( Tranxene ) , oxazepam ( Serax ) , estazolam ( ProSom ) , flurazepam ( Dalmane ) , quazepam ( Doral ) , triazolam ( Halcion ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 23, 2009</verification_date>
	<keyword>Tamiflu</keyword>
	<keyword>Flu</keyword>
	<keyword>Antiviral</keyword>
	<keyword>Neuraminidase Inhibitor</keyword>
	<keyword>Pharmacokinetic Trial</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>HV</keyword>
</DOC>